AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03780075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.70GBq of 177Lu-EB-PSMA-617
Description: Patients were intravenous injected with the dose about 3.70GBq (100 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
Study NCT03897777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training effect on Hypertension and Gut Dysbiosis
Description: the proposed research will: 1) Characterize gut microbial community structure in AA with hypertension in two important compartments that make up the overall gut bacteria in the colon (fecal and colon mucosa); 2) Quantify the relationship between aerobic exercise training and gut bacteria to identify SCFA microbes that adapt to exercise and benefit BP.
Study NCT05318313 — intervention group
Intervention type: OTHER
Intervention: Telerehabilitation
Description: The TR PT evaluation and follow-up visits will be performed via Zoom software
Study NCT06591000 — intervention group
Intervention type: PROCEDURE
Intervention: tricuspid valve replacement
Description: Complete or partial tricuspid valve replacement with mitral allograft/ complete tricuspid valve replacement with biological prosthesis
Study NCT03854773 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block (Group ESPB)
Description: Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
Study NCT03854773 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thoracal paravertebral block (Group TPVB)
Description: Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
Study NCT03854773 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group (group C)
Description: Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
Study NCT03770910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIP receptor antagonist
Description: GIP receptor antagonist
Study NCT03770910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIP receptor agonist
Description: GIP(1-42)
Study NCT03770910 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GIP receptor agonist
Description: GIP(1-42)
Study NCT03770910 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Placebo (vehicle for infusions)
Study NCT03770910 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo (vehicle for infusions)
Study NCT00577837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risedronate
Description: tablet, 5 mg risedronate daily for 6 months
Study NCT00577837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: tablet, 100 mg risedronate monthly for 6 months
Study NCT00577837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: tablet, 150 mg risedronate monthly for 6 months
Study NCT00577837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: experimental
Description: tablet, 200 mg risedronate monthly for 6 months
Study NCT01018147 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4-dimensional computed tomography
Description: Undergo 4-D CT imaging
Study NCT03299868 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: peripherally inserted central catheter (PICC)
Description: comparisons of the safety, efficacy, and patient-perceived satisfaction between the initially routine PICC insertion group (routine PICC group) and general IV access group (general IV group)
Study NCT03299868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: peripherally inserted central catheter (PICC)
Description: comparisons of the safety, efficacy, and patient-perceived satisfaction between the initially routine PICC insertion group (routine PICC group) and general IV access group (general IV group)
Study NCT02413333 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Clear Care Plus contact lens solution
Description: 3% hydrogen peroxide solution with Hydraglyde Moisture Matrix for cleaning, disinfection and overnight storage of contact lenses
Study NCT02413333 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PeroxiClear contact lens solution
Description: 3% hydrogen peroxide solution for cleaning, disinfection and overnight storage of contact lenses
Study NCT02413333 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Silicone hydrogel contact lenses
Description: 2-week/monthly replacement contact lenses per participant's habitual brand
Study NCT04684407 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ROOT CANAL TREATMENT
Description: TWO TYPE OF INTRA CANAL MEDICATION PLACEMENT
Study NCT04684407 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ROOT CANAL TREATMENT
Description: TWO TYPE OF INTRA CANAL MEDICATION PLACEMENT
Study NCT00888004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Study NCT00888004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02824419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methionine
Description: Subject undergoes imaging studies with FDG and with methionine.
Study NCT02824419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOTANOC
Description: Subject undergoes imaging studies with FDG and with DOTANOC.
Study NCT02220231 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: capnothorax
Description: After patient positioning, the capnothorax will be created by insufflation of carbon dioxide in patients undergoing video-assisted thoracoscopic extended thymectomy.
Study NCT03046654 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Trans vaginal sonography
Description: Trans vaginal sonography performed once every 4 weeks from the time of cerclage placement until the time of cerclage removal to evaluate cerclage position and distance from internal and external os'.
Study NCT03046654 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vaginal examination
Description: Vaginal examination performed once every 4 weeks from the time of cerclage placement until the time of cerclage removal to evaluate cervical conditions including cervical dilatation, cervical effacement and pressure on the cerclage.
Study NCT03046654 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Speculum examination
Description: Speculum examination performed once every 4 weeks from the time of cerclage placement until the time of cerclage removal to evaluate cerclage position and vaginal bleeding.
Study NCT02816242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: concept map teaching
Description: teaching anatomy using concept map to improve critical thinking
Study NCT02816242 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: traditional teaching
Description: teaching anatomy using lecture
Study NCT01976117 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enose
Study NCT00824447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oralgen
Description: allergen solution sublingually
Study NCT00824447 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo control
Study NCT02865980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clove extract
Description: in intervention group, first will be washed the Catheter with Betadine after 2 minutes will be used of the clove extract with 2 ml of scrub for 15 seconds. The incidence of inflammation of vascular access will be assessed in patients on hemodialysis for each patient before starting the process over a period of 2 weeks is equivalent to 6 sessions of hemodialysis.
Study NCT02865980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Betadine
Description: in control group, will be washed the Catheter with Betadine
Study NCT03816267 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nebulizer
Description: Nebulization via mask
Study NCT03816267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Delivery of appropriate dose according to weight
Study NCT03816267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: Delivery of appropriate dose according to weight
Study NCT03816267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metered dose inhaler and spacer
Description: Medication will be delivered through inhaler and spacer
Study NCT04310891 — intervention group
Intervention type: RADIATION
Intervention: Markerless Tumour Tracking
Description: Intrafraction Kolovoltage X-ray Imaging using Fiducials
Study NCT02047864 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Study NCT02047864 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Creatine monohydrate
Study NCT05347420 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The visual Neuropad test and the quantitative Neuropad test
Description: The visual screening test includes whether the Neuropad test paper changes completely from blue to pink within 10 minutes (visual screening test a) and the time to complete color change (visual screening test b). the quantitative screening test using a handheld color scanner to scan the rate of color change, which estimated by the slope of the Neuropad color change per minute.
Study NCT02865486 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid emulsion
Description: 1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 2.
Study NCT02865486 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid emulsion
Description: 1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 3.
Study NCT02865486 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid emulsion
Description: 1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 4.
Study NCT04555980 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Warming patch
Description: The warming patch can increase the temp of injection site, result in a blood vessels to dilate, which may have some contribute to decreasing injection pain.
Study NCT04555980 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cotton patch
Description: The Cotton patch will cover the injection site as placebo. It dose not have the function of heating comparing to Warming patch.
Study NCT01140711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fMRI imaging following visual stimulation of food and non-food images
Description: fMRI Scans will be performed in a 3 tesla MRI scanner. All subjects will be scanned for anatomical imaging without injection of contrast material. These structural images will be used to localize the functional data obtained. Functional test will include several measurements of brain activity while viewing visual stimuli.~fMRI allows collection of information about brain activity with good spatial and temporal resolution. Protocols allow rapid assessment of regional activation in different brain regions during exposure to different visual stimuli.It provides a detailed functional map.~Scan test protocol includes anatomical measurement - 3D FSPGE T1w sequence, Asset DTI and repeated fMRI measurements (based on echo EPI, T2 \* w, BOLD sequences). Test paradigms include picture collections of various foods non-food objects similar in size, color and shape.
Study NCT02791074 — intervention group
Intervention type: OTHER
Intervention: NTproBNP
Description: To assess its level in the blood, as a marker of heart failure presence and severity.
Study NCT02791074 — intervention group
Intervention type: OTHER
Intervention: Echocardiography
Description: To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.
Study NCT02791074 — intervention group
Intervention type: OTHER
Intervention: Arterial tonometry
Description: A noninvasive method to obtain arterial pressure waveform.
Study NCT03120247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OTM Dexmedetomidine 1µg/ kg.
Description: Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
Study NCT03120247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OTM Dexmedetomidine 0.75µg/ kg.
Description: Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
Study NCT03120247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OTM Dexmedetomidine 0.5µg/ kg.
Description: Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
Study NCT04555382 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and Urine
Description: Blood and urine samples are collected every twelve hours when the patients are included in the study during observation period.
Study NCT03579251 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Black Men's Care
Description: 12 weeks of behavioral intervention, including an in-person session and two-way SMS, to re-engage in HIV care HIV-positive Black men who have fallen out of care
Study NCT01130233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robotic assisted rectal resection
Description: robotic assisted rectal resection
Study NCT01130233 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic rectal resection
Description: laparoscopic rectal resection
Study NCT01474928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient role played community video
Description: Group two viewed the patient role played community video
Study NCT01474928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: both videos group
Description: Group three viewed both the knowledge and community videos
Study NCT01474928 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pamphlet group
Description: Group four read an educational pamphlet only
Study NCT01474928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physician-led knowledge video
Description: Group one viewed a physician-led knowledge video
Study NCT01474928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community video group
Description: Group two viewed the patient role played community video
Study NCT01474928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: knowledge video
Description: Group one viewed a physician-led knowledge video
Study NCT04039477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KZR-616
Description: Patients will receive KZR-616 SC once weekly. Patients assigned to Arm A will receive 30 mg for 13 weeks and patients assigned to Arm B will receive 30 mg for 1 week then 45 mg for 12 weeks
Study NCT03970070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Complete Perioperative Ostomy Self-Management Telehealth program
Study NCT03970070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03970070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03970070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT01958307 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: The intervention program consists of four individual counseling modules focusing on diet, physical activity and weight monitoring (12th-16th, 16th-20th, 30th-34th week of gestation and 6th-8th week postpartum). The counseling sessions are given by carefully trained midwives or medical staff in combination with prenatal visits and follow a standardized curriculum. Women are provided with brochures including a list of adequate prenatal exercise programs and a pedometer. Furthermore, they receive a chart personalized according to their baseline BMI category to monitor weight development.
Study NCT00806572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hOKT3gamma1(Ala-Ala)
Description: 3 cycles, six months apart, each consisting of 12 daily infusions with 455-1818ug/m2 hOKT3g1(Ala-Ala)
Study NCT00784355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Description: Surgery
Study NCT02957526 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prompts to report symptoms via study app
Description: Weekly prompts to report aromatase inhibitor use in the previous 7 days and treatment-related adverse symptoms via the web-enabled study app.
Study NCT02957526 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Alerts
Description: : Reported symptoms may trigger an email alert to the participant's care team based on predetermined thresholds. Alerts based on certain response thresholds are generated to inform the patient's care team of any concerning responses or trends that emerge from the patient reported outcomes. These alerts will inform providers of particular patient-related adverse events or symptoms requiring an intervention prior to the point that emergent medical care is needed. Information in the alert emails will include the participant's Medical Reference Number (MRN), initials, date of birth, and details about the symptom(s) that generated the alert. Pod nurses instructed to respond to any clinical alerts (sent via email) as soon as possible following standard of care.
Study NCT02957526 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Alerts
Description: : Reported symptoms may trigger an email alert to the participant's care team based on predetermined thresholds. Alerts based on certain response thresholds are generated to inform the patient's care team of any concerning responses or trends that emerge from the patient reported outcomes. These alerts will inform providers of particular patient-related adverse events or symptoms requiring an intervention prior to the point that emergent medical care is needed. Information in the alert emails will include the participant's Medical Reference Number (MRN), initials, date of birth, and details about the symptom(s) that generated the alert. Pod nurses instructed to respond to any clinical alerts (sent via email) as soon as possible following standard of care.
Study NCT02192021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micro needle array-Doxorubicin (MNA-D)
Description: MNA-D patches will be applied to 3-4 CTCL skin patches or plaques at each weekly visit (4/cycle). The initial safety, dose-finding phase will include one cycle of applications and the second phase will include weekly applications (4/cycle) for up to 6-8 cycles.
Study NCT02311868 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SYNBIOTIC (Probinul neutro®)
Description: Probinul neutro® assumed three times a day far from meals as 5 g powder packets dissolved in water. Probinul neutro® contains 5×109 Lactobacillus plantarum, 2×109 Lactobacillus casei subp. rhamnosus and 2×109 Lactobacillus gasseri, 1×109 Bifidobacterium infantis and 1×109 Bifidobacterium longum, 1×109 Lactobacillus acidophilus, 1×109 Lactobacillus salivarus and 1×109 Lactobacillus sporogenes and 5×109 Streptococcus termophilus, prebiotic inulin (2.2 g; VB Beneo Synergy 1) and 1.3 g of tapioca-resistant starch.
Study NCT02311868 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Tapioca-resistant starch powder similar in colour, texture and taste to the symbiotic mixture, assumed three times a day far from meals as 5 g powder packets dissolved in water.
Study NCT00482573 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental local anesthesia
Description: * 2% lidocaine solution with epinephrine 1:100,000~* infusion of 1,8 mL (one cartridge)~* Technic: modified anesthesia of the periodontal ligament (PDLm injection) was performed applying The Wand II Computerized System (Milestone International)
Study NCT00482573 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental local anesthesia
Description: * 2% lidocaine solution without vasoconstrictor~* infusion of 1,8 mL (one cartridge)~* Technic: modified anesthesia of the periodontal ligament (PDLm injection) was performed applying The Wand II Computerized System (Milestone International)
Study NCT03842254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Subcutaneous injection of erythropoietin 10,000 units